
Health ·
FDA Grants Accelerated Approval to New Drug Class for Multiple Myeloma Treatment
The FDA has granted accelerated approval to iberdomide in combination with daratumumab and dexamethasone for adults with relapsed or refractory multiple myeloma, marking the first approval for an entirely new class of cancer drugs called CELMoDs.